Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]

Autor: Wu H, Infante JR, Keedy VL, Jones SF, Chan E, Bendell JC, Lee W, Kirschbrown WP, Zamboni BA, Ikeda S, Kodaira H, Rothenberg ML, Burris III HA, Zamboni WC

Publikováno v: International Journal of Nanomedicine, Vol Volume 14, Pp 5751-5752 (2019)

Wu H, Infante JR, Keedy VL, et al. Int J Nanomedicine. 2015:10;1201—1209 On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article

Externí odkaz: https://doaj.org/article/f7e040c8333d42af9a814346b023d546

Prognostic value of PERCIST and PET/CT metabolic parameters after neoadjuvant treatment in patients with esophageal cancer.

Autor: Martínez A; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain. Electronic address: andres.martineze@salud-juntaex.es., Infante JR; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Quirós J; Servicio de Oncología Radioterápica, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Rayo JI; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Serrano J; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Jiménez P; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Lavado MC; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Baena Á; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.

Publikováno v: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol (Engl Ed)] 2022 Nov-Dec; Vol. 41 (6), pp. 360-367. Date of Electronic Publication: 2022 Oct 12.

Utility of gastrointestinal transit scintigraphy in the evaluation of chronic constipation.

Autor: Infante JR; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Baena A; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Martínez A; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Rayo JI; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Serrano J; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain. Electronic address: justo.serrano@salud-juntaex.es., Jiménez P; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., Lavado MC; Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.

Publikováno v: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol (Engl Ed)] 2022 Sep-Oct; Vol. 41 (5), pp. 292-299. Date of Electronic Publication: 2022 Aug 10.

Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours.

Autor: Karp DD; Investigational Cancer Therapeutics Department, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd #U421, Houston, TX 77030, USA., Camidge DR; Medical Oncology, University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, CO, USA., Infante JR; Department of Drug Development, Sarah Cannon Research Institute, Nashville, TN, USA., Ames TD; Promontory Therapeutics Inc., New York, NY, USA., Price MR; Promontory Therapeutics Inc., New York, NY, USA., Jimeno J; Promontory Therapeutics Inc., New York, NY, USA., Bryce AH; Department of Internal Medicine, Division of Hematology/Oncology, Mayo Clinic Cancer Center, Phoenix, AZ, USA.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2022 May 27; Vol. 49, pp. 101430. Date of Electronic Publication: 2022 May 27 (Print Publication: 2022).

Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancer.

Autor: Drake CG; Columbia University Medical Center, New York, NY, USA. cdrake2@its.jnj.com.; Janssen Research & Development, Spring House, PA, USA. cdrake2@its.jnj.com., Pachynski RK; Washington University of St. Louis, St. Louis, MO, USA., Subudhi SK; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McNeel DG; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Antonarakis ES; Johns Hopkins Kimmel Medical Institute, Baltimore, MD, USA., Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA., Lauer P; Aduro Biotech, Berkeley, CA, USA., Brockstedt D; Aduro Biotech, Berkeley, CA, USA., Patricia D; Janssen Research & Development, Spring House, PA, USA., Wade M; Janssen Research & Development, Spring House, PA, USA., Zudaire E; Janssen Research & Development, Spring House, PA, USA., Bandyopadhyay N; Janssen Research & Development, Raritan, NJ, USA., Parasrampuria DA; Janssen Research & Development, Spring House, PA, USA., Girgis S; Janssen Research & Development, Spring House, PA, USA., Mason GE; Janssen Research & Development, Spring House, PA, USA., Knoblauch RE; Janssen Research & Development, Spring House, PA, USA., Stone N; Janssen Research & Development, Spring House, PA, USA., Infante JR; Janssen Research & Development, Spring House, PA, USA., Gottardis MM; Janssen Research & Development, Spring House, PA, USA., Fong L; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

Publikováno v: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2022 Feb; Vol. 25 (2), pp. 219-228. Date of Electronic Publication: 2021 Jul 13.